The Arzneimittelmarkt-Neuordnungsgesetz  (AMNOG, English translation: "Pharmaceuticals Market Reorganisation Act") is a German law relating to the marketing of pharmaceutical products in Germany. It requires drug manufacturers to submit evidence to the Federal Joint Committee (Germany) to show that their new products are more effective than previous products.  It is credited with reducing the cost of healthcare in Germany.    